Nature’s Toolbox (NTx), a life science company developing domestically-sourced biomanufacturing solutions for delivering personalized therapeutics and biologics, announced it secured $15 million in venture debt from J.P. Morgan. The funding will fuel the deployment of NTx systems across major pharmaceutical, governmental, and clinical organizations.
Even though conventional manufacturing processes and supply chain instability have slowed progress and increased the cost of developing life-saving vaccines and biologics, NTx platforms will utilize U.S. made raw materials and help create an end-to-end domestic supply chain for critical biomaterials. And this system not only reduces costs and simplifies the process but also eliminates harmful byproducts, making it significantly more sustainable than traditional batch methods.
KEY QUOTES:
“As we prepare for the commercial expansion of our distributed biomanufacturing technology, this financing will help us broaden our reach and fulfill our mission to revolutionize biomaterials production by making it more accessible, scalable, and cost-effective. We are excited to have the support of J.P. Morgan and look forward to leveraging their expertise in working with growth-stage life sciences companies.”
– Jamie Coffin, CEO of NTx
“J.P. Morgan is proud to work with NTx as they continue to scale. It’s an exciting time to be working with life sciences companies, and we look forward to supporting the role NTx plays in transforming the way biomaterials are produced and expediting the delivery of personalized therapies.”
– Liz Crum, Co-Head of West Life Sciences within J.P. Morgan’s Innovation Economy business
